Xifaxan Approval History
- FDA approved: Yes (First approved May 25th, 2004)
- Brand name: Xifaxan
- Generic name: rifaximin
- Dosage form: Tablets
- Company: Salix Pharmaceuticals, Inc.
- Treatment for: Traveler's Diarrhea, Hepatic Encephalopathy, Irritable Bowel Syndrome
Xifaxan (rifaximin) is a nonsystemic antibiotic indicated for the treatment of patients with traveler's diarrhea caused by noninvasive strains of Escherichia coli, to reduce the risk of recurrence of hepatic encephalopathy in patients with advanced liver disease, and for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Development History and FDA Approval Process for Xifaxan
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.